A comparison of the inhibitory effects of four volatile anaesthetics on the metabolism of chlorzoxazone, a substrate for CYP2E1, in rabbits

被引:6
|
作者
Tateishi, T
Watanabe, M
Nakura, H
Tanaka, M
Kumai, T
Aoki, T
Kobayashi, S
机构
[1] St Marianna Univ, Sch Med, Dept Pharmacol, Kanagawa, Japan
[2] St Marianna Univ, Sch Med, Dept Anesthesiol, Kanagawa, Japan
关键词
halothane; isoflurane; enflurane; sevoflurane; chlorzoxazone; drug-interaction; rabbits;
D O I
10.1111/j.1399-6576.1998.tb05371.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Halothane inhibits in vitro and in vivo activity of cytochrome P-450 (CYP) 2E1. There are several fluorinated volatile anaesthetics besides halothane, and most of them are defluorinated by CYP2E1. It is unclear whether other fluorinated anaesthetics inhibit the in vivo activity of CYP2E1. Methods: We compared the inhibitory effects of therapeutic concentrations of four inhalational anaesthetics, halothane, enflurane, isoflurane, and sevoflurane, on chlorzoxazone metabolism in rabbits receiving artificial ventilation. Results: All four inhalational anaesthetics decreased arterial blood pressure and increased plasma chlorzoxazone concentration. However, no significant differences in the plasma chlorzoxazone concentration were found between the four anaesthetics. The estimated chlorzoxazone clearance increased after beginning inhalation with all four agents, but no significant difference in clearance was noted between agents. Conclusions: At therapeutic concentrations, the in vivo inhibitory effect on chlorzoxazone metabolism was similar for all four inhalational anaesthetics examined, even though their chemical characteristics and extent of hepatic metabolism differ considerably.
引用
收藏
页码:1028 / 1032
页数:5
相关论文
共 50 条
  • [21] Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses
    Hohmann, Nicolas
    Blank, Antje
    Burhenne, Juergen
    Suzuki, Yosuke
    Mikus, Gerd
    Haefeli, Walter E.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (10) : 2310 - 2320
  • [22] Chlorzoxazone hydroxylation in male and female subjects as an index of CYP2E1 activity.
    Alvarado, L
    Fuentes, MG
    Brown, K
    Dreisbach, AW
    George, WJ
    Lertora, JJ
    JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (01) : A60 - A60
  • [23] Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers
    Bedada, Satish Kumar
    Neerati, Prasad
    PHYTOTHERAPY RESEARCH, 2016, 30 (03) : 463 - 468
  • [24] STUDIES ON INTERINDIVIDUAL VARIATIONS OF CYP2E1 USING CHLORZOXAZONE AS AN IN-VIVO PROBE
    VESELL, ES
    SEATON, TA
    ARAHIM, YI
    PHARMACOGENETICS, 1995, 5 (01): : 53 - 57
  • [25] RELATIONSHIP IN HEALTHY-SUBJECTS BETWEEN CYP2E1 GENETIC POLYMORPHISMS AND THE 6-HYDROXYLATION OF CHLORZOXAZONE - A PUTATIVE MEASURE OF CYP2E1 ACTIVITY
    KIM, RB
    OSHEA, D
    WILKINSON, GR
    PHARMACOGENETICS, 1994, 4 (03): : 162 - 165
  • [26] CYP2E1 Metabolism of Styrene Involves Allostery
    Hartman, Jessica H.
    Boysen, Gunnar
    Miller, Grover P.
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (10) : 1976 - 1983
  • [27] Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation
    Baek, Hye W.
    Bae, Soo K.
    Lee, Myung G.
    Sohn, Young T.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (11) : 2452 - 2462
  • [28] Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers
    Eap, CB
    Schnyder, C
    Besson, J
    Savary, L
    Buclin, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) : 52 - 57
  • [29] Computational docking simulations of oxidative metabolism of CYP2E1
    Cooper, Kasa B.
    Miller, Grover P.
    Perry, Martin D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [30] Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures
    Hartman, Jessica H.
    Letzig, Lynda G.
    Roberts, Dean W.
    James, Laura P.
    Fifer, E. Kim
    Miller, Grover P.
    BIOCHEMICAL PHARMACOLOGY, 2015, 97 (03) : 341 - 349